menu search

Additional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric Endocrinology

Additional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric Endocrinology
Oral Presentation Highlighting Data on 15 Subjects from OraGrowtH212 Trial Supportive of Conclusions from Interim Data Analysis Baseline Characteristics of OraGrowtH210 Trial Subjects Highlighted in Poster Presentation AUSTIN, Texas, March 05, 2023 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase […] The post Additional Data on Lumos OraGrowtH Trials Presented at I... Read More
Posted: Mar 5 2023, 19:00
Author Name: forextv
Views: 102269

Search within

Pages Search Results: